Vaccine Comprising PBMCs Loaded with NKT Cell Ligand and Antigen
Summary
USPTO published patent application US20260091112A1 by CELLID CO., LTD. for an immunotherapeutic vaccine composition comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide (an NKT cell ligand) and tumor antigens. The filing date was September 15, 2023, with publication on April 2, 2026.
What changed
CELLID CO., LTD. filed patent application US20260091112A1 for a vaccine composition using peripheral blood mononuclear cells (PBMCs) loaded with alpha-galactosylceramide (a natural killer T cell ligand) and tumor antigens. The invention addresses malignant tumor treatment by inducing activation of natural killer cells, NKT cells, and cytotoxic T lymphocyte responses. Inventors include Chang-Yuil Kang, Boyeong Song, and Insu Jeon.
Patent applicants and research institutions developing cancer immunotherapies should review this application to assess potential overlap with their own intellectual property or research programs. While patent applications do not create immediate compliance obligations, companies in the cell therapy or cancer immunotherapy space may wish to monitor the prosecution of this application for competitive intelligence purposes.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
VACCINE COMPRISING PERIPHERAL BLOOD MONONUCLEAR CELLS LOADED WITH NATURAL KILLER T CELL LIGAND AND ANTIGEN
Application US20260091112A1 Kind: A1 Apr 02, 2026
Assignee
CELLID CO., LTD.
Inventors
Chang-Yuil Kang, Boyeong Song, Insu Jeon
Abstract
The present invention relates to an immunoprophylactic and therapeutic vaccine comprising peripheral blood mononuclear cells loaded with a natural killer T cell ligand and an antigen, and specifically, to an immunotherapeutic vaccine comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide, a natural killer T cell ligand and a type of glycolipid. A composition of the present invention is easy to obtain because there is no need to separate specific cells from peripheral blood mononuclear cells. In addition, immunization of peripheral blood mononuclear cells loaded with a natural killer T cell ligand and an antigen not only induces significant levels of activation of natural killer cells and natural killer T cells and cytotoxic T lymphocyte responses, but also has a synergistic effect in the treatment of malignant tumors and thus can be helpfully used as an anticancer immunotherapeutic agent.
CPC Classifications
A61K 40/11 A61K 35/15 A61K 35/17 A61K 39/0011 A61K 40/13 A61K 40/17 A61K 40/24 A61K 40/42 A61P 35/00 C12N 15/86 A61K 2039/515 A61K 2039/53 A61K 2039/55572 A61K 2039/55583 A61K 2039/572
Filing Date
2023-09-15
Application No.
19112216
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.